Profile data is unavailable for this security.
About the company
Cipla Limited is an India-based global pharmaceutical company. The Company is engaged in manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). Its geographical segments include India, the United States, South Africa, and the Rest of the World. It has its network of manufacturing, trading and other incidental operations in India and International markets.
- Revenue in INR (TTM)283.51bn
- Net income in INR45.46bn
- Incorporated1935
- Employees30.31k
- LocationCipla LtdMumbai CentralMUMBAI 400013IndiaIND
- Phone+91 2 224826000
- Fax+91 2 224826120
- Websitehttps://www.cipla.com/
More ▼
Mergers & acquisitions
| Acquired company | CIPLA:NSI since announced | Transaction value |
|---|---|---|
| Inzpera Healthsciences Ltd | -10.57% | 12.47m |
| Pulse Pharmaceuticals Pvt Ltd-Doloneuron & Zolsoma Brand | -9.94% | -- |
Data delayed at least 15 minutes, as of Feb 17 2026 04:17 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laurus Labs Ltd | 67.22bn | 8.43bn | 545.58bn | 6.17k | 64.74 | -- | 41.64 | 8.12 | 15.61 | 15.61 | 124.44 | -- | -- | -- | -- | 10,899,350.00 | -- | 8.88 | -- | 14.31 | 58.67 | 48.18 | 12.52 | 11.88 | -- | 7.10 | -- | 13.79 | 10.18 | 14.42 | 123.18 | 7.02 | 23.60 | -- |
| Abbott India Ltd | 68.24bn | 15.24bn | 562.26bn | 3.66k | 36.89 | -- | 35.16 | 8.24 | 717.26 | 717.26 | 3,211.47 | -- | -- | -- | -- | 18,650,260.00 | -- | 22.42 | -- | 30.42 | 46.61 | 44.59 | 22.33 | 18.83 | -- | 79.05 | -- | 73.99 | 9.58 | 9.38 | 17.75 | 18.99 | 27.31 | 34.73 |
| Glenmark Pharmaceuticals Ltd | 164.68bn | 10.65bn | 563.72bn | 13.48k | 52.95 | -- | 34.89 | 3.42 | 37.72 | 37.72 | 583.32 | -- | -- | -- | -- | 12,219,440.00 | -- | 1.33 | -- | 1.92 | 71.68 | 60.15 | 6.47 | 1.82 | -- | 16.41 | -- | 39.62 | 12.77 | 4.60 | 155.14 | 6.18 | -4.24 | 0.00 |
| Alkem Laboratories Ltd | 138.90bn | 23.61bn | 645.95bn | 18.64k | 27.36 | 4.84 | 23.16 | 4.65 | 197.47 | 197.47 | 1,161.71 | 1,116.21 | 0.7427 | 1.71 | 4.97 | 7,451,003.00 | 12.89 | 12.12 | 17.55 | 17.53 | 63.60 | 60.06 | 17.35 | 14.69 | 1.87 | 18.59 | 0.1457 | 28.96 | 2.34 | 9.21 | 20.59 | 13.95 | 13.22 | 12.47 |
| Aurobindo Pharma Ltd | 331.82bn | 34.87bn | 665.37bn | 9.11k | 19.08 | -- | 12.72 | 2.01 | 60.04 | 60.04 | 571.33 | -- | -- | -- | -- | 36,435,560.00 | -- | 8.62 | -- | 12.13 | 59.35 | 53.55 | 10.50 | 12.38 | -- | 14.24 | -- | 7.25 | 9.39 | 6.55 | 9.86 | 4.15 | 11.98 | -- |
| Mankind Pharma Ltd | 138.42bn | 17.75bn | 850.58bn | 27.00k | 47.98 | -- | 31.77 | 6.14 | 42.95 | 43.05 | 334.94 | -- | -- | -- | -- | 5,126,748.00 | -- | 14.93 | -- | 19.39 | 71.39 | 67.59 | 13.00 | 17.70 | -- | 3.64 | -- | 0.00 | 18.98 | 15.79 | 3.90 | 14.03 | 18.41 | -- |
| Zydus Lifesciences Ltd | 260.89bn | 49.38bn | 910.34bn | 27.92k | 18.43 | -- | 14.99 | 3.49 | 49.08 | 49.08 | 259.31 | -- | -- | -- | -- | 9,345,309.00 | -- | 10.92 | -- | 16.35 | 73.12 | 63.12 | 18.91 | 16.73 | -- | -- | -- | 17.81 | 18.90 | 10.27 | 17.96 | 30.92 | 13.63 | 25.74 |
| Lupin Ltd | 261.51bn | 46.45bn | 1.01tn | 19.98k | 20.25 | -- | 16.78 | 3.84 | 108.62 | 108.62 | 603.92 | -- | -- | -- | -- | 13,088,990.00 | -- | 4.53 | -- | 7.16 | 72.62 | 59.70 | 17.86 | 5.95 | -- | 183.80 | -- | 29.13 | 13.48 | 8.11 | 71.41 | -- | 20.11 | 14.87 |
| Dr Reddy's Laboratories Ltd | 346.82bn | 55.68bn | 1.06tn | 26.94k | 18.98 | -- | 14.12 | 3.04 | 66.81 | 66.81 | 416.15 | -- | -- | -- | -- | 12,871,960.00 | -- | 12.15 | -- | 16.94 | 65.76 | 66.18 | 15.92 | 15.81 | -- | 19.79 | -- | 14.69 | 16.54 | 13.26 | 1.38 | 22.84 | 41.26 | 9.86 |
| Cipla Ltd | 283.51bn | 45.46bn | 1.08tn | 30.31k | 23.67 | -- | 19.32 | 3.79 | 56.26 | 56.26 | 350.81 | -- | -- | -- | -- | 9,352,779.00 | -- | 11.89 | -- | 14.49 | 66.53 | 59.55 | 16.03 | 14.74 | -- | 96.40 | -- | 22.40 | 6.88 | 9.97 | 27.93 | 27.80 | 9.14 | 34.08 |
| Torrent Pharmaceuticals Ltd | 127.42bn | 22.72bn | 1.38tn | 16.11k | 60.76 | -- | 44.75 | 10.83 | 67.12 | 67.12 | 376.38 | -- | -- | -- | -- | 7,910,902.00 | -- | 9.54 | -- | 14.72 | 75.64 | 72.56 | 17.83 | 14.14 | -- | 16.34 | -- | 61.09 | 7.35 | 7.72 | 15.39 | 14.48 | 8.51 | 30.36 |
Data as of Feb 17 2026. Currency figures normalised to Cipla Ltd's reporting currency: Indian Rupee INR
28.66%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 27 Nov 2025 | 56.99m | 7.06% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 35.56m | 4.40% |
| SBI Funds Management Ltd.as of 31 Jan 2026 | 24.69m | 3.06% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 21.67m | 2.68% |
| Norges Bank Investment Managementas of 31 Mar 2025 | 20.42m | 2.53% |
| ICICI Prudential Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 18.87m | 2.34% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 15.18m | 1.88% |
| PPFAS Asset Management Private Ltd.as of 31 Jan 2026 | 13.15m | 1.63% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 05 Feb 2026 | 12.89m | 1.60% |
| DSP Asset Managers Pvt. Ltd.as of 31 Jan 2026 | 12.13m | 1.50% |
More ▼
Data from 31 Dec 2025 - 10 Feb 2026Source: FactSet Research Systems Inc.
